CEO and Co-Founder
Joel McComb co-founded BioSpyder Technologies in December 2011 and serves as the company’s CEO. Joel has more than 25 years of life science and business experience. Prior to BioSpyder, he served as the Senior Vice President and General Manager of Life Sciences at Illumina Inc., where he was responsible for managing all array and sequencing products and services related to the research market. Prior to joining Illumina, Joel held two high level positions at General Electric, Inc. He joined GE in 2004 as President, Healthcare Life Sciences-Discovery Systems. In 2007, he served as President of GE Healthcare, Interventional Medicine. Prior to this, he served as President of Life Sciences Discovery Systems (former Amersham Life Sciences). From 2001 to 2004, Joel served as the President and Chief Executive Officer of Innovadyne Technologies and was responsible for strategy and implementation of all its operations, beginning with its startup through its subsequent sale as a profitable business to Gilson, Inc. From 1995 to 2001, Joel held various positions with Beckman Coulter, including roles as the General Manager of Primary Care Diagnostic Division (the former SmithKline Diagnostics) and Director of Corporate Business Development. He has been a Director of Bio-Rad Laboratories, Inc. since July 2014. Joel earned a B.S. in Genetics from the University of California, Davis, and an MBA from the Golden Gate University in San Francisco.
Joanne Yeakley, Ph.D.
VP, R&D and Co-Founder
Jo Yeakley is a co-founder of BioSpyder Technologies and currently serves as VP of Research and Development. She oversees the development program and the execution of projects supported by grants and contracts. Jo manages experimental planning and troubleshooting, directs research personnel, collaborates with contractors and customers, and oversees product manufacturing and service projects. Prior to BioSpyder, Jo held various positions at Illumina from 2001-2011. She was a key member of a team that developed a gene expression assay for measuring transcripts in degraded RNA for detection on an Illumina microarray, and she led product development projects in Molecular Diagnostics, including the first team to take an Illumina product through FDA 510(k) clearance. Before Illumina, Jo worked in various roles in basic research in academia. Jo earned a B.S in Biology and Chemistry from Purdue University, an M.S in Biology from the California Institute of Technology, and a Ph.D. in Biology from the University of California, San Diego.
Bruce Seligmann, Ph.D.
Chief Scientific Officer
Bruce joined BioSpyder as a co-founder in 2012 and currently serves as CSO. He is responsible for exploring new applications for the technology, particularly in the areas of preserved tissues and single cells. Bruce began his career in drug discovery and was a major player in the introduction of combinatorial chemistry into drug discovery as the VP of R&D at Selectide (combinatorial center of focus for Sanofi) and founder/CEO of SIDDOC. He was also the founder, CEO and CSO of High Throughput Genomics, developing and marketing kits and services for expression profiling. As one of the inventors and developers of the intellectual property forming the basis of ArrayPlate and qNPA technology, Bruce recognized the value of the technology and acquired it for High Throughput Genomics. He is an experienced entrepreneur and internationally recognized scientist who is responsible for helping to found and build two successful biotech companies.